美国放射学会非小细胞肺癌再程放疗适用标准系统综述与指南执行摘要
美国放射学会基于系统综述制定非小细胞肺癌胸部再程放疗适用标准指南,纳入52项研究(3项前瞻性),推荐个体化策略、IMRT优先于3DCRT、SBRT用于原发性 alone 失败但中央病灶需谨慎,并给出复合剂量约束以限制高级别/致死性毒性。
要点
- SBRT提高适形性和剂量递增,适用于原发性 alone 失败,但中央病灶需谨慎。
- 同步化疗用于 definitive 再程放疗可改善淋巴结复发结局但增加毒性,应个体化。
- 推荐IMRT而非3DCRT再程放疗;粒子治疗可能进一步降低毒性并安全递增剂量。
核心结论
- 推荐个体化胸部再程放疗方法及共识剂量约束,作为正在进行的再程放疗协作组和NRG Oncology倡议的基础。
研究设计与样本
- 美国放射学会适用标准系统综述与指南,遵循PRISMA系统综述评估截至2020年5月发表的NSCLC胸部再程放疗毒性、局部控制和/或生存研究。
- 251篇文章经排除后52篇(3项前瞻性)构成推荐基础,涉及同步化疗作用、毒性相关因素及最佳再程放疗模式和剂量分割方案。
主要发现
- SBRT提高适形性/剂量递增,对原发性 alone 失败最佳,但中央病灶需谨慎。
- 同步化疗联合 definitive 再程放疗改善淋巴结复发结局但增加毒性,应个体化。
- 超分割再程放疗可能降低长期毒性,但数据有限。
- 推荐IMRT而非3DCRT再程放疗;粒子治疗可能进一步降低毒性并实现更安全剂量递增。
- 急性食管炎/肺炎及晚期肺/心脏/食管/臂丛毒性是再程放疗的剂量限制因素。
关键数值与推荐
- 推荐再程放疗复合剂量约束(2 Gy等效):食管V60<40%,最大点剂量(Dmax)<100 Gy。
- 肺V20<40%;心脏V40<50%;主动脉/大血管Dmax<120 Gy。
- 气管/近端支气管树Dmax<110 Gy;脊髓Dmax<57 Gy;臂丛Dmax<85 Gy。
临床怎么用
- 对选择性的非小细胞肺癌局部区域复发患者,definitive 胸部再程放疗可改善结局。
- 推荐个体化胸部再程放疗方法及共识剂量约束以最小化高级别/致死性毒性风险。
- 同步化疗应个体化,权衡淋巴结复发结局改善与毒性增加。
局限性
- 极少数前瞻性和小型回顾性研究构成该报告推荐剂量约束的基础,需进一步前瞻性研究强化和改进这些指南。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Definitive thoracic reirradiation can improve outcomes for select patients with non-small cell lung cancer (NSCLC) with locoregional recurrences. To date, there is a lack of systematic reviews on safety or efficacy of NSCLC reirradiation and dedicated guidelines. This American Radium Society Appropriate Use Criteria Systematic Review and Guidelines provide practical guidance on thoracic reirradiation safety and efficacy and recommends consensus of strategy, techniques, and composite dose constraints to minimize risks of high-grade/fatal toxicities. Preferred Reporting Items for Systematic Reviews and Meta-Analyses systematic review assessed all studies published through May 2020 evaluating toxicities, local control and/or survival for NSCLC thoracic reirradiation. Of 251 articles, 52 remained after exclusions (3 prospective) and formed the basis for recommendations on the role of concurrent chemotherapy, factors associated with toxicities, and optimal reirradiation modalities and dose-fractionation schemas. Stereotactic body radiation therapy improves conformality/dose escalation and is optimal for primary-alone failures, but caution is needed for central lesions. Concurrent chemotherapy with definitive reirradiation improves outcomes in nodal recurrences but adds toxicity and should be individualized. Hyperfractionated reirradiation may reduce long-term toxicities, although data are limited. Intensity modulated reirradiation is recommended over 3D conformal reirradiation. Particle therapy may further reduce toxicities and enable safer dose escalation. Acute esophagitis/pneumonitis and late pulmonary/cardiac/esophageal/brachial plexus toxicities are dose limiting for reirradiation. Recommended reirradiation composite dose constraints (2 Gy equivalents): esophagus V60 <40%, maximum point dose (Dmax) < 100 Gy; lung V20 <40%; heart V40 <50%; aorta/great vessels Dmax < 120 Gy; trachea/proximal bronchial tree Dmax < 110 Gy; spinal cord Dmax < 57 Gy; brachial plexus Dmax < 85 Gy. Personalized thoracic reirradiation approaches and consensus dose constraints for thoracic reirradiation are recommended and serve as the basis for ongoing Reirradiation Collaborative Group and NRG Oncology initiatives. As very few prospective and small retrospective studies formed the basis for generating the dose constraint recommended in this report, further prospective studies are needed to strengthen and improve these guidelines.
引用
- Simone CB, Amini A, Chetty IJ, et al. American Radium Society Appropriate Use Criteria Systematic Review and Guidelines on Reirradiation for Non-Small Cell Lung Cancer Executive Summary. Int J Radiat Oncol Biol Phys. 2025. PMID: 40185207. doi:10.1016/j.ijrobp.2025.03.056
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。